The pathergy test and Behçet’s syndrome in Britain

P. G. Davies, J. N. Fordham, J. R. Kirwan, C. G. Barnes, and W. J. Dinning

From the Bone and Joint Research Unit, The London Hospital Medical College; the Department of Rheumatology, The London Hospital, London E1 IBB; and Moorfields Eye Hospital, City Road, London ECI

SUMMARY Skin hypersensitivity to needle puncture (pathergy test) together with a positive HLA B5 antigen has been reported as a diagnostic test for Behçet’s syndrome (BS) in Turkish patients. We have studied the pathergy test by 2 methods in 7 healthy volunteers who have the HLA B5 (Bw 51 split) antigen and 19 patients with BS. The test was negative in all the normal volunteers, and only one of the 19 patients with BS had a positive test by one of the 2 methods. Cluster analysis of our patients and those reported from Turkey showed no difference in their clinical features. The positivity of the pathergy test, and hence its diagnostic usefulness, seem to differ between Britain and Turkey, and we conclude that this difference is not related to the possession of the HLA B5 (Bw 51 split) antigen.

The cutaneous hypersensitivity reaction to percutaneous trauma by needle prick (positive 'pathergy' test) has been reported as being a common feature of Behçet’s syndrome, particularly in Japan and Turkey, both being countries with a high prevalence of this condition. Yazıcı et al. have recently proposed that the combination of a positive pathergy test and the presence of the HLA B5 antigen is a diagnostic marker of Behçet’s syndrome, their dual negativity virtually excluding the diagnosis. In that study 82% of 49 patients had a positive pathergy test and 84% carried HLA B5. Both tests were positive in 65% of the Turkish patients. However, the reliability of the pathergy test as a diagnostic feature has been questioned. We have therefore studied the pathergy test in a group of patients with Behçet’s syndrome seen at Moorfields Eye Hospital and the London Hospital, Whitechapel, and a group of normal subjects who possess the HLA B5 (Bw 51 split) antigen.

Patients and methods

Seven normal subjects who carry the HLA Bw 51 antigen (drawn from laboratory staff who had had histocompatibility typing performed to provide a pool of subjects of known HLA status) and 19 patients with ‘definite’ Behçet’s syndrome according to the diagnostic criteria of Mason and Barnes and O’Duffy were included in the study.

The pathergy test was performed by 2 methods. The skin of the flexor aspect of the left forearm was cleaned with 70% isopropyl alcohol and pricked intradermally with a sterile hypodermic needle (size 25G). After similar skin preparation 0.1 ml of 0.9% saline was injected intradermally on the flexor aspect of the right forearm. The injection sites were read at 48 hours by the patient and classified as negative, positive (red and raised), or strongly positive (red and raised with a pustule) with reference to illustrations provided. These illustrations were similar to those shown in the report of Yazıcı et al. The patient then returned the result by post.

Cluster analysis was performed on the data from 19 patients reported on here and those of the 42 patients reported on by Yazıcı et al. This analysis combines cases into groups, or clusters, with similar clinical profiles in a stepwise manner until a single large cluster including all the data is established. The chart, or ‘dendrogram’, it produces displays the interrelationships between the cases, with cases of high similarity being linked near the top of the dendrogram.

The database consisted of the age and sex of each patient and the presence or absence at any time of aphthous ulceration, genital ulceration, uveitis, skin lesions (pyoderma and/or erythema nodosum), arthritis, thrombophlebitis, and a positive pathergy test. HLA B5 status was not included, as this was unknown in our 19 patients.
Results

Details of the age, sex, and ethnic origin of the normal HLA Bw 51 carrying subjects are shown in Table 1, together with their pathergy response. In all 7 subjects the pathergy response was negative by both methods.

The clinical features and country of birth of the 19 patients with Behçet's syndrome are shown in Table 2, which also indicates which features were active at the time of study. Eighteen patients reported a negative pathergy test by both methods, and one patient reported a positive response to the intradermal saline injection only.

Cluster analysis of all 68 patients (19 from this study plus 49 from Yazıcı et al.) showed that the 19 patients reported here are scattered throughout the group and do not form a separate cluster (Fig. 1). This was the case even though the pathergy test results were included in the data-base, which would tend to separate the London patients from those seen in Turkey. Analysis of the Turkish data alone showed that the pattern of relationships between the Turkish cases was almost identical to that obtained with our patients, indicating that the overall pattern of clustering was not dependent on the inclusion of the London data nor on the result of the pathergy test.

Discussion

These results confirm the general impression that the pathergy test is seldom positive in British patients suffering from Behçet's syndrome. It is interesting to note that our one patient who had a positive pathergy test was a Greek Cypriot. The frequency of other clinical features of Behçet's syndrome, in particular pulmonary and gastrointestinal lesions, varies in different parts of the world, the former having been reported mainly from Turkey and the latter from Japan. The marked difference in frequency of positive pathergy tests in the London and the Turkish patients would suggest that they are representative of 2 different syndromes. If this were the case, differences other than in cutaneous hypersensitivity would be found between the groups. Cluster analysis shows, however, that there was no clear separation between these 2 groups of patients in terms of their other clinical features.

The explanation for this observed difference in pathergy testing is not clear. The possibility that cutaneous hypersensitivity may occur in normal people in Turkey or in other medical conditions has

Table 1 Details of normal subjects carrying HLA Bw 51 and their pathergy response

<table>
<thead>
<tr>
<th>Country of origin</th>
<th>Age</th>
<th>Sex</th>
<th>Pathery</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turkey</td>
<td>32</td>
<td>M</td>
<td>—</td>
</tr>
<tr>
<td>Spain</td>
<td>37</td>
<td>M</td>
<td>—</td>
</tr>
<tr>
<td>Iraq</td>
<td>32</td>
<td>M</td>
<td>—</td>
</tr>
<tr>
<td>British Caucasian</td>
<td>28</td>
<td>M</td>
<td>—</td>
</tr>
<tr>
<td>&quot;</td>
<td>35</td>
<td>M</td>
<td>—</td>
</tr>
<tr>
<td>&quot;</td>
<td>24</td>
<td>F</td>
<td>—</td>
</tr>
<tr>
<td>&quot;</td>
<td>28</td>
<td>F</td>
<td>—</td>
</tr>
</tbody>
</table>

Table 2 Details of patients and pathergy response

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Country of birth</th>
<th>Age</th>
<th>Sex</th>
<th>Aphthous ulceration</th>
<th>Genital ulceration</th>
<th>Uveitis</th>
<th>Skin lesions</th>
<th>Arthritis</th>
<th>Thrombo-phlebitis</th>
<th>Pathery</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Britain</td>
<td>39</td>
<td>M</td>
<td>+*</td>
<td>+</td>
<td>-</td>
<td>+*</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>2</td>
<td>Britain</td>
<td>49</td>
<td>F</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>3</td>
<td>Britain</td>
<td>29</td>
<td>M</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>4</td>
<td>Britain</td>
<td>35</td>
<td>M</td>
<td>+*</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>5</td>
<td>Barbados</td>
<td>46</td>
<td>M</td>
<td>+</td>
<td>+</td>
<td>*</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>6</td>
<td>Britain</td>
<td>41</td>
<td>M</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>7</td>
<td>Britain</td>
<td>60</td>
<td>M</td>
<td>+*</td>
<td>-</td>
<td>+</td>
<td>+*</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>8</td>
<td>Britain</td>
<td>60</td>
<td>M</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>9</td>
<td>Britain</td>
<td>68</td>
<td>F</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>10</td>
<td>Britain</td>
<td>59</td>
<td>M</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>11</td>
<td>Britain</td>
<td>41</td>
<td>F</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>12</td>
<td>Britain</td>
<td>39</td>
<td>M</td>
<td>+*</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>13</td>
<td>Kenya (Asian)</td>
<td>31</td>
<td>M</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>14</td>
<td>Britain</td>
<td>30</td>
<td>M</td>
<td>+</td>
<td>+</td>
<td>+*</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>15</td>
<td>Italy</td>
<td>30</td>
<td>M</td>
<td>+</td>
<td>+</td>
<td>+*</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>16</td>
<td>Cyprus</td>
<td>27</td>
<td>M</td>
<td>+</td>
<td>-</td>
<td>+*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>17</td>
<td>Britain</td>
<td>34</td>
<td>M</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>18</td>
<td>Jordan</td>
<td>33</td>
<td>M</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>19</td>
<td>Britain</td>
<td>33</td>
<td>F</td>
<td>+</td>
<td>+</td>
<td>+*</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Active at time of testing.
been studied by Tüzün et al. In a group of 90 healthy and diseased controls only 3 (2 with recurrent aphthous ulceration and one with erythema nodosum) had positive pathergy. Alternatively, British patients may have less active disease. While 7 of our patients were in a quiescent phase, 4 had recurrent aphthous ulceration (2 of whom had one other clinical feature as well), and 8 had uveitis requiring treatment with steroids and/or chlorambucil at the time of this study.

Histological study of the pathergy response has shown a predominantly polymorphonuclear (PMN) infiltrate in the first 24 hours. It has been suggested that this is secondary to an increase in PMN chemotaxis. Accordingly, reduced PMN chemotaxis may explain the absence of cutaneous hypersensitivity in our patients. Fifteen of these patients have, however, been the subject of a previous report which showed their PMN chemotomility to be increased.

HLA B5 was the second marker of Behçet's syndrome proposed by Yazıcı et al., but we do not know its frequency in our patients. Two British studies of Behçet's syndrome have shown a frequency of 17.8% and 29% of the HLA B5 antigen compared with 84% in Turkey. It is possible therefore that only a minority of our patients would carry this marker, and accordingly it would not be of diagnostic value. The presence of both HLA B5 and positive pathergy in 65% of the Turkish patients, raises the possibility that HLA B5 may directly or indirectly confer some predisposition to cutaneous hypersensitivity. This seems unlikely, as all the normal subjects carrying HLA Bw 51 that we have studied had negative pathergy tests.

We are grateful to Professor H. Festenstein and Dr Alonso for allowing us access to their tissue typing panel.

References

The pathergy test and Behçet's syndrome in Britain

The pathergy test and Behçet's syndrome in Britain.

P G Davies, J N Fordham, J R Kirwan, C G Barnes and W J Dinning

Ann Rheum Dis 1984 43: 70-73
doi: 10.1136/ard.43.1.70

Updated information and services can be found at:
http://ard.bmj.com/content/43/1/70

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/